{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:56:58Z","timestamp":1792785418066,"version":"4.5.0"},"reference-count":118,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China","award":["82304316, 82221002, 22220102001, 22173118, 22307112"],"award-info":[{"award-number":["82304316, 82221002, 22220102001, 22173118, 22307112"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Young Scientists Fund of Natural Science Foundation of Hunan Province of China","award":["2024JJ6554"],"award-info":[{"award-number":["2024JJ6554"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/13543776.2026.2722028","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:53:31Z","timestamp":1787162011000},"page":"965-990","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Selective PARP1 inhibitors (2021\u20132025): patent landscape, structural evolution, and future therapeutic opportunities"],"prefix":"10.1080","volume":"36","author":[{"given":"Jilong","family":"Duan","sequence":"first","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Duan","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]},{"name":"Hong Kong Baptist University","place":["Hong Kong SAR, People\u2019s Republic of China"]},{"name":"Hong Kong Baptist University","place":["Hong Kong SAR, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongling","family":"Gu","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yang","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Kang","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchao","family":"Deng","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Cao","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, People\u2019s Republic of China"]},{"name":"Hong Kong Baptist University","place":["Hong Kong SAR, People\u2019s Republic of China"]},{"name":"Hong Kong Baptist University","place":["Hong Kong SAR, People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2015.00885"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.09.019"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012724"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3240"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3376"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12030446"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109042"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells15040348"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061289"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.018"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180682"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12070964"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1205-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0428-3"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03439-y"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557518666180816111749"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2016.0007"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201426RR"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2023.106336"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020394"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2020-0891"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2021.01.014"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz120"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.12.082"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl840"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2013.01.007"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21442"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.53"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3201"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081188"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14023773"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874467211205010102"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-019-01802-z"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.610"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10283-1"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2024.12.021"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63600-z"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.03.008"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2335"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.39979"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi800018a"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168207"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016573"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax6367"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202404277"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01335"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.202"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.14"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0301"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01012"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01725"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-2609"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2094"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02276"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118650"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00185"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02463"},{"key":"e_1_3_4_65_1","unstructured":"Sha W Liu Y Liu Y et al. Preparation of PARP1 inhibitors. Shenzhen Yangli Pharmaceutical Technology Co. Ltd.; 2024."},{"key":"e_1_3_4_66_1","unstructured":"Trzoss L Dong Q Kaldor SW et al. Preparation of piperazine derivatives as PARP1 inhibitors useful in treatment of cancer. XinThera Inc.; 2022."},{"key":"e_1_3_4_67_1","unstructured":"Fan W Dong Y Tang C et al. Azaquinolone compound and its pharmaceutically acceptable salt and application in preparation of PARP1 inhibitors for preventing and treating PARP1-related diseases. Shandong Xuande Pharmaceutical Technology Co. Ltd.; 2024."},{"key":"e_1_3_4_68_1","unstructured":"Deng Y Tian Y Jia Y et al. PARP inhibitor pharmaceutical composition comprising same and application. Keythera (Suzhou) Bio-Pharmaceuticals Co. Limited; 2023."},{"key":"e_1_3_4_69_1","unstructured":"Paliwal S Samatar AA Cripe LS. Preparation of multicyclic compounds as PARP1 inhibitors. SLAP Pharmaceuticals LLC.; 2023."},{"key":"e_1_3_4_70_1","unstructured":"Jia T Wang T Li G. Preparation of fused lactam ring compound as PARP1 inhibitor. Chengdu Zenitar Biomedical Technology Co. Ltd.; 2025."},{"key":"e_1_3_4_71_1","unstructured":"Kankanala J Pettigrew JD Pham SM. Preparation of piperazinyl picolinamide derivatives as PARP1 modulators. 1CBIO Inc.; 2024."},{"key":"e_1_3_4_72_1","unstructured":"Gao S Hou Y Li J et al. Aryl urea PARP1 inhibitor preparation method and use thereof. Haihe Biopharma Co. Ltd.; 2024."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108939"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115709"},{"key":"e_1_3_4_75_1","unstructured":"Packer MJ Johannes JW Hande SM et al. Preparation of azaquinolone derivatives as PARP1 inhibitors for treatment of cancer. AstraZeneca AB; 2021."},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja9530376"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00703-8"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.8b00011"},{"key":"e_1_3_4_79_1","unstructured":"Zhang W. Azaquinolinone compounds as PARP inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer. 2023."},{"key":"e_1_3_4_80_1","unstructured":"Li Y Wang W Chen L et al. Heteroaryl derivative PARP inhibitor and use thereof. Haisco Pharmaceutical Group Co. Ltd.; 2023."},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0379-2"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8CC07813K"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00821"},{"key":"e_1_3_4_84_1","unstructured":"Li Y Chen L He T et al. 6-oxo-5 6-dihydro-1 5-naphthyridine derivatives as PARP-1 degradation agents and their preparation pharmaceutical compositions and use in the treatment of cancer. Haisco Pharmaceutical Group Co. Ltd.; 2023."},{"key":"e_1_3_4_85_1","unstructured":"Wang T Shen Z Talbot EPA et al. Piperazine derivatives as PARP1 inhibitors. Ningbo Newbay Technology Development Co. Ltd.; 2023."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01122"},{"key":"e_1_3_4_87_1","unstructured":"Li X Chen Y Yang F et al. Preparation of nitrogen-containing heterocyclic compounds as PARP1 inhibitor for treatment\/prevention of cancer. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Shanghai Hengrui Pharmaceutical Co. Ltd.; 2022."},{"key":"e_1_3_4_88_1","unstructured":"Wei Y Li W Yuan H et al. Piperazino ring-containing derivative pharmaceutically acceptable salt thereof preparation method therefor and application thereof. Acerand Therapeutics (Hong Kong) Limited; 2023."},{"key":"e_1_3_4_89_1","unstructured":"Zhang J Zhu S Qi X. Heteroaromatic compound and application as PARP1 and PARP2 inhibitor. Orimos Therapeutics Co. Ltd.; 2023."},{"key":"e_1_3_4_90_1","unstructured":"Li M Chen Y Chen C-Y et al. Hexahydropyrrolo[3 4-c]pyrrole-multicyclic compounds as PARP1 inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer. Laekna Therapeutics Shanghai Co. Ltd.; 2024."},{"key":"e_1_3_4_91_1","unstructured":"Fan W Tang C. Preparation of substituted azaquinolone compounds as PARP inhibitors and its applications. Sanuojin Pharmaceutical Technology (Wuxi) Co. Ltd.; 2024."},{"key":"e_1_3_4_92_1","unstructured":"Ko MS Kim IH Han Y et al. Preparation of dihydrooxazinylcarboxamide derivative as PARP1 inhibitor and pharmaceutical composition comprising same. Chong Kun Dang Pharmaceutical Corp.; 2025."},{"key":"e_1_3_4_93_1","unstructured":"Zhu H. Parp1 inhibitors for the treatment of diseases. Protheragen Inc.; 2025."},{"key":"e_1_3_4_94_1","unstructured":"Wang N. Preparation of quinoxaline\/naphthyridine derivatives as PARP1 inhibitor. Zhejiang Wenda Pharmaceutical Technology Co. Ltd.; 2023."},{"key":"e_1_3_4_95_1","unstructured":"Zhang X Quan X Li J et al. Preparation of 1\u2019-((7-ethyl-6-oxo-5 6-dihydro-1 5-naphthyridin-3-yl)methyl)-N-methyl-1\u2019 2\u2018 3\u2019 6\u2019-tetrahydro-[3 4\u2019-bipyridine]-6-carboxamide as PARP1 inhibitor. Nanjing Sanhome Pharmaceutical Co. Ltd.; 2023."},{"key":"e_1_3_4_96_1","unstructured":"Xu Z Xia L. Compound having triple bond structure and pharmaceutical composition thereof and use thereof. Shanghai Yingli Pharmaceutical Co. Ltd.; 2025."},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115836"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116160"},{"key":"e_1_3_4_99_1","unstructured":"Li X Dong H Cai G et al. Nitrogen-containing heterocyclic compounds as PARP1 inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Shanghai Hengrui Pharmaceutical Co. Ltd.; 2022."},{"key":"e_1_3_4_100_1","unstructured":"Ren L Lyssikatos JP. Preparation of fused tetracyclic selective PARP1 inhibitors. Enliven Inc.; 2024."},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0499256"},{"key":"e_1_3_4_102_1","unstructured":"Twibanire J-DAK Cook C Atapatu S et al. Preparation of quinazolinone derivatives as poly(ADO-ribose) polymerase 1 (PARP-1) inhibitors. Waverley Pharma Inc.; 2025."},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00747"},{"key":"e_1_3_4_104_1","unstructured":"Kim E Park C Oh S et al. Preparation of isoquinolinone derivatives and pharmaceutical compositions thereof for prevention or treatment of poly(ADP-ribose)polymerase-1 (PARP-1)-associated diseases. The Industry & Academic Cooperation In Chungnam National University (Iac) Kukje Pharma Co. Ltd.; 2021."},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-509"},{"key":"e_1_3_4_106_1","unstructured":"Cowley P Wise A. Deuterated PARP1 inhibitor compounds. Duke Street Bio Limited; 2025."},{"key":"e_1_3_4_107_1","unstructured":"Cowley PM Wise A. Preparation of 1 2-dihydroisoquinolin-1-one and related compounds as PARP1 inhibitors. Duke Street Bio Limited; 2025."},{"key":"e_1_3_4_108_1","unstructured":"Cowley PM Wise A Hill C. PARP1 inhibitors used as pharmaceutical compounds. Duke Street Bio Limited; 2023."},{"key":"e_1_3_4_109_1","unstructured":"Cowley PM Wise A. Preparation of fused 3 4-dihydropyrimidine-4-one compounds as PARP1 inhibitors for treating cancers. Duke Street Bio Limited; 2025."},{"key":"e_1_3_4_110_1","unstructured":"Cowley P Wise A. Preparation of substituted pyrrolopyrazinones and their analogs as PARP1 inhibitors. Duke Street Bio Limited; 2025."},{"key":"e_1_3_4_111_1","unstructured":"Cowley PM Wise A. Preparation of 3-ethyl-1 2-dihydropyridin-2-one-linked 5-(piperazin-1-yl)pyridine-2-carboxamide derivatives as PARP1 inhibitor compounds. Duke Street Bio Limited; 2024."},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00411"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02460"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01370-z"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0423"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118287"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2026.109698"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae236"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2021.10.001"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.1504"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2722028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2722028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2722028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:39:45Z","timestamp":1790865585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2722028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":118,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/13543776.2026.2722028"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2722028","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}